

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

On March 24, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Hardin

PATENT  
Attorney Docket No.: 018623-008050US  
Client Reference No.: EPI0080.50 US

RECEIVED

MAR 30 2000

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Application No.: 09/017,743

Filed: February 3, 1998

For: HLA BINDING PEPTIDES AND  
THEIR USES

Examiner: DeBrino, Marianne

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

RECEIVED

APR 04 2000

TECH CENTER 1600/2900

Box SEQUENCE  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed March 6, 2000, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 4, lines 14 and 15, replace "Figure 1 shows binding motifs for peptides capable of binding HLA alleles sharing the B7-like specificity." with "Figure 1 shows the B7-like cross-reactive motif (SEQ ID NO:141)".